Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$27.90
-0.5%
$27.22
$12.00
▼
$32.21
$4.52B2.182.30 million shs2.48 million shs
ALMR
Alamar Biosciences
$26.40
-7.9%
$30.31
$18.84
▼
$39.61
$1.83BN/A448,637 shs712,583 shs
Sotera Health Company stock logo
SHC
Sotera Health
$15.91
-1.9%
$17.77
$13.09
▼
$19.85
$4.54B1.942.70 million shs1.73 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€15.71
-1.4%
€18.74
€12.05
▼
€24.01
€4.76B0.8571,630 shs752,316 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-1.44%-4.85%+14.86%+7.93%+85.15%
ALMR
Alamar Biosciences
-6.00%-9.70%+1.85%-16.24%+2,867,999,900.00%
Sotera Health Company stock logo
SHC
Sotera Health
-0.43%-0.55%-9.59%-17.17%+2.72%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+3.10%+10.66%-16.54%-29.85%-25.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$27.90
-0.5%
$27.22
$12.00
▼
$32.21
$4.52B2.182.30 million shs2.48 million shs
ALMR
Alamar Biosciences
$26.40
-7.9%
$30.31
$18.84
▼
$39.61
$1.83BN/A448,637 shs712,583 shs
Sotera Health Company stock logo
SHC
Sotera Health
$15.91
-1.9%
$17.77
$13.09
▼
$19.85
$4.54B1.942.70 million shs1.73 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€15.71
-1.4%
€18.74
€12.05
▼
€24.01
€4.76B0.8571,630 shs752,316 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-1.44%-4.85%+14.86%+7.93%+85.15%
ALMR
Alamar Biosciences
-6.00%-9.70%+1.85%-16.24%+2,867,999,900.00%
Sotera Health Company stock logo
SHC
Sotera Health
-0.43%-0.55%-9.59%-17.17%+2.72%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+3.10%+10.66%-16.54%-29.85%-25.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.63
Moderate Buy$30.318.65% Upside
ALMR
Alamar Biosciences
2.43
Hold$33.0025.00% Upside
Sotera Health Company stock logo
SHC
Sotera Health
2.55
Moderate Buy$21.0031.99% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.67
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ALMR, STVN, SHC, and ADPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
ALMR
Alamar Biosciences
DowngradeHold (C-) ➝ Sell (D+)
11/18/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
DowngradeHold (C) ➝ Hold (C-)
11/18/2026
Sotera Health Company stock logo
SHC
Sotera Health
Set Price TargetHold$20.00
11/10/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Boost Price TargetBuy$32.00 ➝ $34.00
11/4/2026
ALMR
Alamar Biosciences
UpgradeSell (D+) ➝ Hold (C-)
11/4/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
DowngradeOutperform ➝ Market Perform
11/4/2026
ALMR
Alamar Biosciences
Boost Price TargetBuy$34.00 ➝ $36.00
11/4/2026
Sotera Health Company stock logo
SHC
Sotera Health
Lower Price TargetUnderweight$17.00 ➝ $15.00
11/4/2026
Sotera Health Company stock logo
SHC
Sotera Health
Lower Price TargetOverweight$22.00 ➝ $20.00
11/4/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Lower Price TargetNeutral$23.00 ➝ $16.00
11/4/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Lower Price TargetBuy$26.00 ➝ $20.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$276.98M16.31N/AN/A$1.14 per share24.47
ALMR
Alamar Biosciences
$74.21M24.72N/AN/A$4.37 per share6.04
Sotera Health Company stock logo
SHC
Sotera Health
$1.16B3.91$1.25 per share12.74$2.57 per share6.19
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.34B3.55€0.90 per share17.41€6.06 per share2.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.45N/AN/AN/A-23.67%-23.95%-8.01%2/4/2027 (Estimated)
ALMR
Alamar Biosciences
-$29.82M-$2.15N/AN/AN/A-48.22%-78.71%-20.08%N/A
Sotera Health Company stock logo
SHC
Sotera Health
$77.94M$0.6026.5216.40N/A14.11%38.46%7.66%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5827.0922.131.5811.24%10.51%6.22%N/A

Latest ALMR, STVN, SHC, and ADPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.10$0.02+$0.12$0.02$71.57 million$83.90 million
11/4/2026Q3 2026
ALMR
Alamar Biosciences
-$0.22-$0.19+$0.03-$0.19N/A$33.55 million
11/3/2026Q3 2026
Sotera Health Company stock logo
SHC
Sotera Health
$0.2687$0.29+$0.0213$0.20$319.86 million$324.89 million
11/3/2026Q3 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.17€0.16-€0.01€0.15N/A€326.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
ALMR
Alamar Biosciences
N/AN/AN/AN/AN/A
Sotera Health Company stock logo
SHC
Sotera Health
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
1.82
3.97
3.87
ALMR
Alamar Biosciences
N/A
9.49
7.87
Sotera Health Company stock logo
SHC
Sotera Health
3.04
3.13
2.91
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.73
1.19

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
ALMR
Alamar Biosciences
N/A
Sotera Health Company stock logo
SHC
Sotera Health
91.03%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
ALMR
Alamar Biosciences
N/A
Sotera Health Company stock logo
SHC
Sotera Health
15.36%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
624161.88 million152.65 millionOptionable
ALMR
Alamar Biosciences
22269.48 millionN/AN/A
Sotera Health Company stock logo
SHC
Sotera Health
3,000285.63 million241.76 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 million300.72 millionOptionable

Recent News About These Companies

Stevanato Group S.p.A. (STVN) - What Are Brokerages Saying About This Stock?
Here’s What Drove Stevanato Group’s (STVN) Q3 Outperformance
KeyCorp Estimates Stevanato Group FY2027 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$27.90 -0.15 (-0.53%)
Closing price 03:58 PM Eastern
Extended Trading
$27.93 +0.03 (+0.11%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Alamar Biosciences NASDAQ:ALMR

$26.40 -2.28 (-7.95%)
As of 03:59 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

Sotera Health stock logo

Sotera Health NASDAQ:SHC

$15.91 -0.30 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$15.91 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€15.71 -0.22 (-1.38%)
Closing price 03:59 PM Eastern
Extended Trading
€15.68 -0.03 (-0.19%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.